Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021

Jantien A. Backer; Dirk Eggink; Stijn P. Andeweg; Irene K. Veldhuijzen; Noortje van Maarseveen; Klaas Vermaas; Boris Vlaemynck; Raf Schepers; Susan van den Hof; Chantal B. E. M. Reusken; Jacco Wallinga

doi:10.2807/1560-7917.ES.2022.27.6.2200042

Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021

Jantien A. Backer^*
, Dirk Eggink
, Stijn P. Andeweg
, Irene K. Veldhuijzen
, Noortje van Maarseveen
, Klaas Vermaas
, Boris Vlaemynck
, Raf Schepers
, Susan van den Hof
, Chantal B. E. M. Reusken
, Jacco Wallinga

^*Corresponding author for this work

National Institute of Public Health and the Environment
Saltro Diagnostic Center for Primary Care
University Medical Center Utrecht
SYNLAB
Leiden University Medical Center

Research output: Contribution to journal › Article › Academic › peer-review

38 Downloads (Pure)

Abstract

The SARS-CoV-2 Omicron variant has a growth advantage over the Delta variant because of higher transmissibility, immune evasion or shorter serial interval. Using S gene target failure (SGTF) as indication for Omicron BA.1, we identified 908 SGTF and 1,621 non-SGTF serial intervals in the same period. Within households, the mean serial interval for SGTF cases was 0.2-0.6 days shorter than for non-SGTF cases. This suggests that the growth advantage of Omicron is partly due to a shorter serial interval.

Original language	English
Journal	Euro surveillance
Volume	27
Issue number	6
DOIs	https://doi.org/10.2807/1560-7917.ES.2022.27.6.2200042
Publication status	Published - 10 Feb 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.2807/1560-7917.ES.2022.27.6.2200042

Shorter-serial-intervals-in-sars-cov-2-cases-with-omicron-ba1-variant-compared-with-delta-variant-the-netherlands-13-.pdfFinal published version, 154 KBLicence: CC BY

Cite this

Backer, J. A., Eggink, D., Andeweg, S. P., Veldhuijzen, I. K., van Maarseveen, N., Vermaas, K., Vlaemynck, B., Schepers, R., van den Hof, S., Reusken, C. B. E. M., & Wallinga, J. (2022). Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021. Euro surveillance, 27(6). https://doi.org/10.2807/1560-7917.ES.2022.27.6.2200042

@article{d852a180b7c249ae8460c333c757b67d,

title = "Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021",

abstract = "The SARS-CoV-2 Omicron variant has a growth advantage over the Delta variant because of higher transmissibility, immune evasion or shorter serial interval. Using S gene target failure (SGTF) as indication for Omicron BA.1, we identified 908 SGTF and 1,621 non-SGTF serial intervals in the same period. Within households, the mean serial interval for SGTF cases was 0.2-0.6 days shorter than for non-SGTF cases. This suggests that the growth advantage of Omicron is partly due to a shorter serial interval.",

author = "Backer, \{Jantien A.\} and Dirk Eggink and Andeweg, \{Stijn P.\} and Veldhuijzen, \{Irene K.\} and \{van Maarseveen\}, Noortje and Klaas Vermaas and Boris Vlaemynck and Raf Schepers and \{van den Hof\}, Susan and Reusken, \{Chantal B. E. M.\} and Jacco Wallinga",

note = "Funding Information: Funding: The study was financed by the Netherlands Ministry of Health, Welfare and Sport. This project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation programme - project EpiPose (grant agreement number 101003688). Funding Information: The study was financed by the Netherlands Ministry of Health, Welfare and Sport. This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (grant agreement number 101003688). Publisher Copyright: {\textcopyright} 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.",

year = "2022",

month = feb,

day = "10",

doi = "10.2807/1560-7917.ES.2022.27.6.2200042",

language = "English",

volume = "27",

journal = "Euro surveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "6",

}

Backer, JA, Eggink, D, Andeweg, SP, Veldhuijzen, IK, van Maarseveen, N, Vermaas, K, Vlaemynck, B, Schepers, R, van den Hof, S, Reusken, CBEM & Wallinga, J 2022, 'Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021', Euro surveillance, vol. 27, no. 6. https://doi.org/10.2807/1560-7917.ES.2022.27.6.2200042

TY - JOUR

T1 - Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021

AU - Backer, Jantien A.

AU - Eggink, Dirk

AU - Andeweg, Stijn P.

AU - Veldhuijzen, Irene K.

AU - van Maarseveen, Noortje

AU - Vermaas, Klaas

AU - Vlaemynck, Boris

AU - Schepers, Raf

AU - van den Hof, Susan

AU - Reusken, Chantal B. E. M.

AU - Wallinga, Jacco

N1 - Funding Information: Funding: The study was financed by the Netherlands Ministry of Health, Welfare and Sport. This project has received funding from the European Union’s Horizon 2020 research and innovation programme - project EpiPose (grant agreement number 101003688). Funding Information: The study was financed by the Netherlands Ministry of Health, Welfare and Sport. This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (grant agreement number 101003688). Publisher Copyright: © 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

PY - 2022/2/10

Y1 - 2022/2/10

N2 - The SARS-CoV-2 Omicron variant has a growth advantage over the Delta variant because of higher transmissibility, immune evasion or shorter serial interval. Using S gene target failure (SGTF) as indication for Omicron BA.1, we identified 908 SGTF and 1,621 non-SGTF serial intervals in the same period. Within households, the mean serial interval for SGTF cases was 0.2-0.6 days shorter than for non-SGTF cases. This suggests that the growth advantage of Omicron is partly due to a shorter serial interval.

AB - The SARS-CoV-2 Omicron variant has a growth advantage over the Delta variant because of higher transmissibility, immune evasion or shorter serial interval. Using S gene target failure (SGTF) as indication for Omicron BA.1, we identified 908 SGTF and 1,621 non-SGTF serial intervals in the same period. Within households, the mean serial interval for SGTF cases was 0.2-0.6 days shorter than for non-SGTF cases. This suggests that the growth advantage of Omicron is partly due to a shorter serial interval.

UR - https://www.scopus.com/pages/publications/85124499732

U2 - 10.2807/1560-7917.ES.2022.27.6.2200042

DO - 10.2807/1560-7917.ES.2022.27.6.2200042

M3 - Article

C2 - 35144721

SN - 1025-496X

VL - 27

JO - Euro surveillance

JF - Euro surveillance

IS - 6

ER -

Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this